NovAccel adds $1.82M to its seed round for cancer-isotope accelerator
What's the deal? NovAccel, a Japanese deep-tech startup developing a compact superconducting electron accelerator for medical isotopes, has raised about US$2.23M (roughly $1.82 million) in a seed extension round. XTech VenturesDealroom has a profile for this one. Try Dealroom →, Inoue Co., Ltd., and individual investors backed the round through a third-party share allotment.
What's the endgame? NovAccel is building RiSA — a small, low-power accelerator designed specifically to produce actinium-225 (Ac-225), an isotope central to targeted alpha therapy for cancer. The company aims to supply Ac-225 from Japan to the world.
Where's the money going? The funds will support development of RiSA and the Ac-225 production process, equipment and quality-control systems for sample supply, and business development at home and abroad. NovAccel plans to continue fundraising.
Why now? The round extends a larger post-seed raise earlier this year and lands as demand for targeted alpha therapy grows against a tight global supply of Ac-225. NovAccel is also working with domestic research institutions and, via US subsidiary NovAccel Isotopes Inc., with overseas pharmaceutical firms.
What investors say: XTech Ventures called the company an "all-star team" even at seed stage (translated from Japanese). Inoue Co. said it would contribute its materials-sourcing and supply-chain strength to help NovAccel reach mass production and stable supply.
What could go wrong? The sum alone does not prove commercial progress. NovAccel still needs to establish manufacturing and quality control, then convert that into stable supply and customer contracts.
The signal: Investment in Ac-225 supply is accelerating globally — US rivals NiowaveDealroom has a profile for this one. Try Dealroom → and NorthStar are building production capacity backed by tens of millions of dollars. NovAccel's extension keeps a Japanese contender in a race defined less by capital than by who can deliver reliable isotopes.
Read more: prtimes.jp
Image credit: Generated with Gemini